Astragaloside IV inhibits ventricular remodeling and improves fatty acid utilization in rats with chronic heart failure

Chronic heart failure (CHF) is the end-stage of many cardiovascular diseases and severely affects the patients’ lifespan. Inhibiting ventricular remodeling is thus a primary treatment target for CHF patients. Astragaloside IV (AS-IV) can improve cardiac function and protect myocardial cells. The stu...

Descripción completa

Detalles Bibliográficos
Autores principales: Tang, Bin, Zhang, Jin-Guo, Tan, Hong-Yong, Wei, Xi-Qing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Portland Press Ltd. 2018
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6048210/
https://www.ncbi.nlm.nih.gov/pubmed/29301869
http://dx.doi.org/10.1042/BSR20171036

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6048210/
https://www.ncbi.nlm.nih.gov/pubmed/29301869
http://dx.doi.org/10.1042/BSR20171036

Ejemplares similares